Meridian Bioscience (VIVO) Getting Somewhat Favorable News Coverage, Report Finds

News headlines about Meridian Bioscience (NASDAQ:VIVO) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Meridian Bioscience earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.4681261820242 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Shares of VIVO remained flat at $$14.80 during mid-day trading on Thursday. The stock had a trading volume of 30,379 shares, compared to its average volume of 294,971. Meridian Bioscience has a 1 year low of $13.23 and a 1 year high of $16.45. The company has a quick ratio of 3.96, a current ratio of 5.82 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $630.39, a P/E ratio of 22.05 and a beta of 0.96.

How to Become a New Pot Stock Millionaire

Meridian Bioscience (NASDAQ:VIVO) last issued its earnings results on Thursday, January 25th. The company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.01. The firm had revenue of $52.30 million for the quarter, compared to the consensus estimate of $49.00 million. Meridian Bioscience had a return on equity of 17.00% and a net margin of 10.46%. The company’s revenue was up 11.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.15 earnings per share. equities research analysts expect that Meridian Bioscience will post 0.72 EPS for the current fiscal year.

A number of analysts have recently commented on the company. BidaskClub downgraded Meridian Bioscience from a “hold” rating to a “sell” rating in a research note on Saturday, February 3rd. Zacks Investment Research downgraded Meridian Bioscience from a “buy” rating to a “hold” rating in a research note on Friday, April 13th. Finally, Canaccord Genuity upped their target price on Meridian Bioscience from $14.00 to $16.00 and gave the stock a “hold” rating in a research note on Friday, January 26th.

TRADEMARK VIOLATION NOTICE: “Meridian Bioscience (VIVO) Getting Somewhat Favorable News Coverage, Report Finds” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://ledgergazette.com/2018/04/19/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-meridian-bioscience-vivo-share-price.html.

Meridian Bioscience Company Profile

Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and viral diseases, respiratory and parasitic infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.

Insider Buying and Selling by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply